News

Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
Why Shares of Pfizer Soared Today
In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...
Pfizer CEO details talks with Trump administration on tariffs, Most Favored Nations pricing
Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...
Pfizer raises 2025 EPS guidance to $2.90–$3.10 while targeting margin expansion through $7.7B cost savings by 2027
Pfizer Q2 2025 earnings show 10% revenue growth, raised EPS guidance, strong R&D, and operational execution. Explore growth drivers and policy risks.
Buy Pfizer Stock At $24?
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Pfizer beats in Q2 earnings, reaffirms 2025 outlook
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...
Fierce Pharma5h
Pfizer CEO touts 'extremely productive' talks with Trump administration as MFN pricing, tariff threats close in
As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...
BioSpace5h
Pfizer CEO in Touch With President Over Most Favored Nation Drug Pricing
Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...
Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain.
Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...